• Ionis Pharmaceuticals $IONS is picking up a $75 million milestone payment from Bayer related to IONIS-FXIRx. Ionis plans to start a Phase IIb study with IONIS-FXIRX in patients with end-stage renal disease who are on hemodialysis. “We recently completed a Phase II study in patients with end-stage renal disease on hemodialysis, in which IONIS-FXIRx demonstrated robust reductions in Factor XI activity and no treatment-related major bleeding, ” stated B. Lynne Parshall, COO at Ionis Pharmaceuticals.
• Inventiva has steered onto the Paris market, reaping $51 million from its IPO as it preps for a mid-stage NASH study. The biotech prices its shares at the low end of the range.
• Ipsen is adding 100 workers from Merrimack under its recent cancer drug deal, according to the Boston Business Journal.
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 21,000+ biopharma pros who read Endpoints News by email every day.Free Subscription